Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Operator-Assisted Oscilla Audiometry as a Basis for Hearing Aid Fitting (The Oscilla Validation Study)

15 de novembro de 2026 atualizado por: Lene Dahl Siggaard, Aalborg University Hospital

Validation of Operator-Assisted Oscilla Audiometry as a Diagnostic Tool and Basis for Hearing Aid Fitting in Adults With Uncomplicated Hearing Loss: A Blinded Non-Inferiority Randomised Controlled Trial

The purpose of this study is to find out whether hearing tests performed with the Oscilla A60 audiometer, where the patient largely tests themselves with minimal staff assistance, are accurate enough to be used for diagnosing hearing loss and as the sole basis for fitting hearing aids. Adults referred for their first hearing aids at Aalborg University Hospital will have their hearing tested both with the Oscilla audiometer and by a trained audiology assistant at the same visit. Participants are then randomly assigned to receive hearing aids fitted based on either the Oscilla hearing test or the audiology assistant's hearing test. The main questions are: (1) Do the Oscilla results agree with the audiology assistant's results for both air-conduction and bone-conduction hearing thresholds? (2) Do participants fitted based on the Oscilla test report a hearing benefit that is not worse than that of participants fitted based on the standard test, two months after fitting?

Visão geral do estudo

Descrição detalhada

Demand for audiometric testing in public hearing clinics is increasing due to population ageing. Operator-assisted automated audiometry may expand capacity, but its use as the sole basis for hearing aid prescription, and its accuracy for bone-conduction (BC) thresholds, has not been established. This single-site study at the Department of Audiology, Aalborg University Hospital (locations in Aalborg and Hobro) enrols 268 first-time hearing aid users with uncomplicated, symmetric sensorineural hearing loss.

At Visit 1, all participants undergo both Oscilla A60 audiometry (air conduction [AC] 250-8000 Hz; BC 250-4000 Hz) and standard manual audiometry by an audiology assistant (reference standard), in randomised order. Agreement between methods is assessed with Bland-Altman analysis against pre-specified acceptance criteria (95% CI of bias within ±5 dB; 95% limits of agreement within ±15 dB for AC and ±20 dB for BC). After confirmation of eligibility, participants are randomised 1:1, stratified by hearing loss severity (PTA-4 ≤45 vs >45 dB HL) and location, to hearing aid fitting based on the Oscilla audiogram or the audiology assistant audiogram. All participants are fitted bilaterally with BTE/RIC hearing aids to the NAL-NL2 target, verified with automated real-ear measurements (within ±5 dB). Volume control and app connectivity are disabled until the two-month follow-up. The primary patient-reported outcome is the change in SSQ12 total score from baseline to two months post-fitting, with a non-inferiority margin of -0.81 points. Secondary outcomes are IOI-HA, daily hearing aid use (data logging) and SSQ12 subscales. The study is a clinical investigation under Article 82 of Regulation (EU) 2017/745.

Tipo de estudo

Intervencional

Inscrição (Estimado)

268

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Lene D Siggaard, MD, PhD
  • Número de telefone: +45 20633492
  • E-mail: lene.dahl@rn.dk

Estude backup de contato

Locais de estudo

      • Aalborg, Dinamarca, 9000
        • Department of Audiology, Aalborg University Hospital
        • Contato:
        • Contato:
          • Lene D Siggaard, MD, PhD
          • Número de telefone: +4520633492
          • E-mail: lene.dahl@rn.dk
      • Hobro, Dinamarca, 9500
        • Hearing Clinic, Aalborg University Hospital
        • Contato:
        • Contato:
          • Lene D Siggaard, MD, PhD
          • Número de telefone: +4520633492
          • E-mail: lene.dahl@rn.dk

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Adults (≥18 years) referred for first-time hearing aid fitting at the Department of Audiology, Aalborg University Hospital
  • Uncomplicated sensorineural hearing loss as defined by the Danish national clinical guidelines
  • Hearing thresholds exceeding 20 dB HL at two or more frequencies in the range 0.5-4 kHz
  • Pure-tone average (PTA-4; 0.5, 1, 2, 4 kHz) ≥30 dB HL in the better ear
  • Symmetric hearing loss (PTA-4 difference between ears ≤15 dB)
  • Word discrimination score ≥25% (DANTALE I at PTA + 40 dB HL)
  • Danish native speaker
  • No prior hearing aid experience
  • Able to complete questionnaires online or on paper
  • Written informed consent

Exclusion Criteria:

  • Air-conduction thresholds exceeding 80 dB HL at two or more frequencies
  • Air-bone gap >15 dB at one or more frequencies below 1 kHz
  • Fluctuating hearing loss (e.g., Ménière's disease) or ongoing ototoxic medication
  • Ear surgery (ear canal, middle ear or inner ear) within the past 12 months
  • Hearing loss classified as complicated according to national clinical guidelines
  • Visual or motor impairment precluding independent use of the Oscilla system
  • Candidates for in-the-ear hearing aids only (all participants are fitted with BTE or RIC hearing aids)

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Diagnóstico
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Oscilla-based fitting

Hearing aids fitted bilaterally to NAL-NL2 targets based on the Oscilla A60 audiogram, verified with automated real-ear measurement. Volume control and app connectivity disabled for two months (linked interventions: Paired audiometry and Oscilla-based hearing aid fitting).

At Visit 1, all participants undergo both operator-assisted Oscilla A60 audiometry (AudioConsole v4.6.0; AC and BC thresholds; operator places the BC headband only) in a quiet room (<50 dB SPL) and manual pure-tone audiometry (AC and BC, ISO 8253-1) by a qualified audiology assistant in a sound-attenuating booth, in randomised order.

Bilateral BTE/RIC hearing aid fitting to NAL-NL2 targets using the Oscilla A60 audiogram as the sole audiometric basis, verified with auto-REM (within ±5 dB of target). Other names: Oscilla A60 Diagnostic Audiometer.

Comparador Ativo: Manual audiometry-based fitting

Hearing aids fitted bilaterally to NAL-NL2 targets based on the audiogram obtained by a qualified audiology assistant, verified with automated real-ear measurement. Volume control and app connectivity disabled for two months (linked interventions: paired audiometry and manual audiometry-based hearing aid fitting).

At Visit 1, all participants undergo both operator-assisted Oscilla A60 audiometry (AudioConsole v4.6.0; AC and BC thresholds; operator places the BC headband only) in a quiet room (<50 dB SPL) and manual pure-tone audiometry (AC and BC, ISO 8253-1) by a qualified audiology assistant in a sound-attenuating booth, in randomised order.

Bilateral BTE/RIC hearing aid fitting to NAL-NL2 targets using the audiology assistant audiogram, verified with auto-REM (within ±5 dB of target). Standard clinical practice.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Agreement between Oscilla A60 and manual audiometry for air-conduction thresholds
Prazo: Visit 1 (Week 0)

Bland-Altman mean difference (Oscilla minus manual) and 95% limits of agreement in dB, plus mean absolute difference, at 0.5, 1, 2 and 4 kHz separately. Agreement is acceptable if the 95% CI of the bias is within ±5 dB and the 95% limits of agreement are within ±15 dB. Both ears included, clustering handled with a mixed-effects model.

Visit 1 (Week 0)
Agreement between Oscilla A60 and manual audiometry for bone-conduction thresholds
Prazo: Visit 1 (Week 0)

As above for bone-conduction thresholds at 0.5, 1, 2 and 4 kHz. Agreement is acceptable if the 95% CI of the bias is within ±5 dB and the 95% limits of agreement are within ±20 dB.

Visit 1 (Week 0)
Change in SSQ12 total score
Prazo: Baseline (Week 0) and 2 months after hearing aid fitting

Speech, Spatial and Qualities of Hearing Scale, 12-item version; total score = mean of 12 items, range 0-10, higher = better. Non-inferiority if the lower bound of the two-sided 95% CI for the between-group difference in change (Oscilla minus control) is above -0.81 points.

Baseline (Week 0) and 2 months after hearing aid fitting

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
IOI-HA total score
Prazo: 2 months after hearing aid fitting

International Outcome Inventory for Hearing Aids, Danish version; 7 items scored 1-5, total range 7-35, higher = better outcome. Compared between groups

2 months after hearing aid fitting
Daily hearing aid use
Prazo: From hearing aid fitting to 2 months after fitting

Mean daily hearing aid usage time in hours/day from the hearing aid data log, compared between groups

From hearing aid fitting to 2 months after fitting
Change in SSQ12 subscale scores
Prazo: Baseline (Week 0) and 2 months after hearing aid fitting

Change in the speech, spatial and qualities subscale scores (each range 0-10, higher = better)

Baseline (Week 0) and 2 months after hearing aid fitting

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Lene D Siggaard, MD, PhD, Department of Otolaryngology, Head- and Neck Surgery and Audiology, Aalborg University Hospital

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de dezembro de 2026

Conclusão Primária (Estimado)

31 de outubro de 2027

Conclusão do estudo (Estimado)

31 de outubro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

15 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

15 de novembro de 2026

Primeira postagem (Real)

19 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

19 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

15 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • F2026-115
  • Regional Innovation Fund (Número de outro subsídio/financiamento: North Denmark Region)
  • Danish Medicines Agency (Identificador de registro: 16-0302-225)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Descrição do plano IPD

Pseudonymised individual participant data may be shared upon reasonable request after publication, subject to approval under the GDPR and Danish data protection law and a data processing agreement.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever